Drug Profile
Indatuximab ravtansine - Biotest AG
Alternative Names: Anti-myeloma monoclonal antibody-DM4 immunoconjugate BT-062; BT-062; Maytansinoid-conjugated anti-myeloma monoclonal antibody BT-062; N2'-Deacetyl-N2'-[4-Methyl-4-(Oxobuthyldithio)-1-Oxopentyl]-Maytansine-Chimerized Anti-Cd138 Igg4 Monoclonal Antibody; nBT062Latest Information Update: 27 Apr 2022
Price :
$50
*
At a glance
- Originator Biotest
- Developer Biotest AG
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Maytansinoids; Monoclonal antibodies
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Bladder cancer; Breast cancer; Multiple myeloma
Most Recent Events
- 25 Apr 2022 Biotest AG has been acquired by Grifols
- 31 Dec 2020 Biotest terminates its license agreement with Immunogen for maytansinoid ADC technology
- 04 Feb 2020 No development reported - Phase-II for Bladder cancer (Metastatic disease, Monotherapy, Second-line therapy or greater) in Belgium, Germany (IV)